
Sign up to save your podcasts
Or


The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.
By BioSpace4.9
1313 ratings
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

91,297 Listeners

30,609 Listeners

43,687 Listeners

8,801 Listeners

977 Listeners

4,420 Listeners

1,173 Listeners

1,993 Listeners

56,944 Listeners

9,556 Listeners

337 Listeners

6,097 Listeners

6,592 Listeners

34 Listeners

21 Listeners